Abstract Efforts are ongoing to develop effective controlled-release therapeutic systems through innovative functional targeted drug delivery systems (TDDS). Functional polymeric nanocarriers are crucial in delivering therapeutic drugs efficiently into tumors. This study designed a redox/pH-responsive functional drug delivery platform with ligands for targeting MC7 breast cancer cells using a core-shell biocompatible magnetic nanocarrier. The process involved synthesizing oleic acid-coated Fe3O4@SiO2 nanoparticles, modifying pluronic F127 (PF 127) with maleic anhydride and aminating it to form PF127-NH2, linking L-cysteine to PF127-NH2, and condensing carboxymethyl-β-cyclodextrin (CM-β-CD) to PF127-NH2/L-cysteine, which was targeted by folic acid (FA). The resulting PF127-NH2/L-cysteine-CM-β-CD-FA formed LCMNPs-SS in the presence of oleic acid-coated Fe3O4@SiO2. Doxorubicin (DOX) was used as a model drug and loaded into the LCMNPs-SS nanocarrier. The LCMNPs-SS nanocarrier exhibited excellent properties for controlled release, with release rate and level controllable by adding an external magnet and adjusting the DTT concentration. Additionally, the LCMNPs-SS nanocarrier could disassemble under the effects of oxidant or pH, allowing for fine-tuning of drug release in response to temperature and pH or multiple stimuli.
No takes yet. Share an insight, caveat, or question.
Ehsanimehr et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: